Date: 2012-01-05
Type of information:
Compound: small molecule drugs against oncology-relevant protein-protein interactions
Company: Boehringer Ingelheim (Germany) FORMA Therapeutics (USA)
Therapeutic area: Cancer Oncology
Type agreement: R&D
Action mechanism:
Disease: cancer
Details: FORMA Therapeutics has entered into a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer. The agreement will focus on discovering small molecule drugs against oncology-relevant protein-protein interactions.
Financial terms: Under the terms of the collaboration, FORMA will receive a total of $65 million in up-front payments and research funding to screen for and optimize compounds against multiple oncology targets over the next four years. FORMA could be eligible for up to $750 million in pre-commercial milestones for programs resulting from the collaboration. Further financial details were not disclosed.
Latest news:
